Company profile: Precirix
1.1 - Company Overview
Company description
- Provider of radio-immunotherapeutic drugs for cancer patients, developing single-domain antibody CAM-H2 targeting HER2 combined with iodine-131 in Phase I/II for HER2-positive metastatic breast, gastric, and gastroesophageal cancers; FAP-targeting radiopharmaceutical program entering clinical trials; and a theranostic approach using imaging to select patients before treatment.
Products and services
- CAM-H2: Single-domain antibody targeting HER2, combined with iodine-131, in Phase I/II trials for HER2-positive metastatic breast, gastric, and gastroesophageal cancers, clinical-stage
- Theranostic approach: Method using an imaging version of a product to select patients, followed by a therapeutic dose for treatment, imaging-guided
- FAP-targeting program: Program targeting Fibroblast Activation Protein, transitioning into clinical trials, aimed at developing radiopharmaceuticals for cancer treatment, translational
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Precirix
Koelis
HQ: France
Website
- Description: Provider of medical imaging solutions for urologists, including KOELIS Trinity MRI/US prostate biopsy system for accurate needle guidance in prostate cancer diagnosis and treatment; OBT Fusion for prostate tracking and core location recording with precise targeting; 3D Ultrasound with motion compensation; 2nd Look Option; and transperineal and transrectal tools with 3D probes, holders, guides, and accessories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Koelis company profile →
MediWise
HQ: United Kingdom
Website
- Description: Provider of medical research and development, pioneering cutting-edge wireless devices for medical diagnostics and monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MediWise company profile →
Novelos Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research, development, and commercialization focused on oxidized glutathione.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novelos Therapeutics company profile →
C4X Discovery
HQ: United Kingdom
Website
- Description: Provider of NMR-based 3D molecular structure determination to optimize drug design and development, partnering with pharma to generate better, safer products. Offers Conformetrix 4D structural design technology, 4Sight visualizer, PatientSeek for genetic patient stratification, and programs including oral α4β7 integrin inhibitors, IL-17A inhibitors (licensed to Sanofi), and NRF2 activators (licensed to AstraZeneca).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C4X Discovery company profile →
Advanced Accelerator Applications
HQ: France
Website
- Description: Provider of targeted radioligand therapies and precision imaging radioligands, offering LUTATHERA: a radioligand therapy using lutetium Lu 177 dotatate for treating tumors; PLUVICTO: a therapeutic radioligand containing lutetium Lu 177 vipivotide tetraxetan; diagnostic PET imaging kits NETSPOT, LOCAMETZ, and SOMAKIT TOC; and LysaKare to reduce renal radiation exposure during peptide-receptor radionuclide therapy with LUTATHERA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advanced Accelerator Applications company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Precirix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Precirix
2.2 - Growth funds investing in similar companies to Precirix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Precirix
4.2 - Public trading comparable groups for Precirix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →